Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NxStage clears US hurdle in Medisystems acquisition:

This article was originally published in Clinica

Executive Summary

US antitrust authorities have completed a review of NxStage Medical's proposed buyout of its long-term business partner Medisystems Corporation, bringing NxStage closer to purchasing the developer of disposables used in dialysis and blood treatment. The firm says it has begun to implement organisational changes in anticipation of the transaction, expected to close during the fourth quarter of 2007. Lawrence, Massachusetts-based NxStage has promoted that Michael Webb to the newly-created position of senior vice-president of quality, regulatory and clinical affairs, whereas, upon the closing of the deal, Phil Licari will resign as senior vice-president and chief operating officer to pursue other opportunities. The deal, signed in June, is valued at around $78.7m (see Clinica No 1259, p 18).

You may also be interested in...

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts